prikaz prve stranice dokumenta Vaccination provides protection from respiratory deterioration and death among hospitalized COVID‐19 patients: Differences between vector and mRNA vaccines
  Preuzmi
PDF 857.66 KB
Znanstveni rad - Izvorni znanstveni rad
Vaccination provides protection from respiratory deterioration and death among hospitalized COVID‐19 patients: Differences between vector and mRNA vaccines
Journal of Medical Virology, 94 (2022), 6; 2849-2854. https://doi.org/10.1002/jmv.27666
Bušić, Nikolina; Lucijanić, Tomo; Baršić, Bruno; Lukšić, Ivica; Bušić, Iva; Kurdija, Goran; Barbić, Ljubo; Kunštek, Sanja; Jelić, Tea; Lucijanić, Marko

Citirajte ovaj rad

Bušić, N., Lucijanić, T., Baršić, B., Lukšić, I., Bušić, I., Kurdija, G. ... Lucijanić, M. (2022). Vaccination provides protection from respiratory deterioration and death among hospitalized COVID‐19 patients: Differences between vector and mRNA vaccines. Journal of Medical Virology, 94. (6), 2849-2854. doi: 10.1002/jmv.27666

Bušić, Nikolina, et al. "Vaccination provides protection from respiratory deterioration and death among hospitalized COVID‐19 patients: Differences between vector and mRNA vaccines." Journal of Medical Virology, vol. 94, br. 6, 2022, str. 2849-2854. https://doi.org/10.1002/jmv.27666

Bušić, Nikolina, Tomo Lucijanić, Bruno Baršić, Ivica Lukšić, Iva Bušić, Goran Kurdija, Ljubo Barbić, Sanja Kunštek, Tea Jelić i Marko Lucijanić. "Vaccination provides protection from respiratory deterioration and death among hospitalized COVID‐19 patients: Differences between vector and mRNA vaccines." Journal of Medical Virology 94, br. 6 (2022): 2849-2854. https://doi.org/10.1002/jmv.27666

Bušić, N., et al. (2022) 'Vaccination provides protection from respiratory deterioration and death among hospitalized COVID‐19 patients: Differences between vector and mRNA vaccines', Journal of Medical Virology, 94(6), str. 2849-2854. doi: 10.1002/jmv.27666

Bušić N, Lucijanić T, Baršić B, Lukšić I, Bušić I, Kurdija G, i sur.. Vaccination provides protection from respiratory deterioration and death among hospitalized COVID‐19 patients: Differences between vector and mRNA vaccines. Journal of Medical Virology [Internet]. 06.2022. [pristupljeno 19.12.2024.];94(6):2849-2854. doi: 10.1002/jmv.27666

N. Bušić, et al., "Vaccination provides protection from respiratory deterioration and death among hospitalized COVID‐19 patients: Differences between vector and mRNA vaccines", Journal of Medical Virology, vol. 94, br. 6, str. 2849-2854, Lipanj 2022. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:303609. [Citirano: 19.12.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:303609
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Vaccination provides protection from respiratory deterioration and death among hospitalized COVID‐19 patients: Differences between vector and mRNA vaccines
AutorNikolina Bušić
AutorTomo Lucijanić
AutorBruno Baršić
AutorIvica Lukšić
AutorIva Bušić
AutorGoran Kurdija
AutorLjubo Barbić
AutorSanja Kunštek
AutorTea Jelić
AutorMarko Lucijanić
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA MAKSILOFACIJALNU KIRURGIJU SA STOMATOLOGIJOM)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Kirurgija
Sažetak (engleski)
Outcomes of 109 hospitalized COVID-19 patients who received at least one vaccine dose 14 or more days prior the disease onset were retrospectively compared to control cohort of 109 age, sex, and Charlson comorbidity index-matched patients chosen among 2990 total hospitalized patients in our tertiary-level institution in a period from January to June 2021. Among 109 vaccinated patients, 84 patients were partially and 25 fully vaccinated. Vaccinated patients experienced significantly lower 30 days mortality (30% vs. 49%; hazard ratio [HR]: 0.56 [0.37-0.85]; p = 0.008), less frequently required high flow oxygen therapy (17% vs. 34%; HR: 0.45 [0.26-0.76]; p = 0.005), and mechanical ventilation (8% vs. 18%; HR: 0.41 [0.20-0.88]; p = 0.027) in comparison to the matched cohort of unvaccinated patients. More favorable survival was observed in patients receiving vector in comparison to messenger RNA (mRNA) vaccine types in unadjusted analysis (30 days mortality 18% vs. 40%; HR: 0.45 [0.25-0.79]; p = 0.034). In the multivariable Cox regression analysis model both mRNA (HR: 0.59 [0.36-0.98]; p = 0.041) and vector vaccine types (HR: 0.30 [0.15-0.60]; p < 0.001) were associated with improved survival in comparison to unvaccinated patients, independently of age (HR: 1.03 [1.01-1.06]; p = 0.011), male sex (HR: 1.78 [1.14-2.76]; p = 0.010), severity of illness (HR: 2.06 [1.36-3.10]; p < 0.001) and functional status on admission (HR: 1.42 [1.07-1.85]; p = 0.013).
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaJournal of Medical Virology
Brojčani podacivol. 94, br. 6, str. 2849-2854
p-ISSN0146-6615
e-ISSN1096-9071
DOIhttps://doi.org/10.1002/jmv.27666
URN:NBNurn:nbn:hr:105:303609
Datum objave publikacije2022-06
URL dokumentahttps://onlinelibrary.wiley.com/doi/10.1002/jmv.27666
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2022-07-19 10:06:18